Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from The Bile Acid Signaling Axis: Deciphering the Roles of FXR and TGR5 in Hepatic Steatosis, Fibrosis, and Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
The Role of the Farnesoid X Receptor in Kidney Health and Disease: A Potential Therapeutic Target in Kidney Diseases
10.1038/s12276-023-00932-2 · 2023 · External reference
FXR: Structures, Biology, and Drug Development for NASH and Fibrosis Diseases
10.1038/s41401-021-00849-4 · 2022 · External reference
Identification of a Nuclear Receptor for Bile Acids
10.1126/science.284.5418.1362 · 1999 · External reference
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
10.1016/s1097-2765(00)80348-2 · 1999 · External reference
The Role of Farnesoid X Receptor in Metabolic Diseases, and Gastrointestinal and Liver Cancer
10.1038/s41575-020-00404-2 · 2021 · External reference
Novel Therapeutic Targets for Cholestatic and Fatty Liver Disease
10.1136/gutjnl-2021-324305 · 2022 · External reference
Crosstalk Between Bile Acid‐Activated Receptors and Microbiome in Entero‐Hepatic Inflammation
10.1016/j.molmed.2021.12.006 · 2022 · External reference
Effect of Different Bile Acids on the Intestine Through Enterohepatic Circulation Based on FXR
10.1080/19490976.2021.1949095 · 2021 · External reference
TGR5, Not Only a Metabolic Regulator
2016 · External reference
The Bile Acid Membrane Receptor TGR5: A Novel Pharmacological Target in Metabolic, Inflammatory and Neoplastic Disorders
10.3109/10799893.2013.802805 · 2013 · External reference
Bile Acids and Their Receptors: Modulators and Therapeutic Targets in Liver Inflammation
10.1007/s00281-022-00935-7 · 2022 · External reference
The Bile Acid TGR5 Membrane Receptor: From Basic Research to Clinical Application
10.1016/j.dld.2013.10.021 · 2014 · External reference
A G Protein‐Coupled Receptor Responsive to Bile Acids
10.1074/jbc.m209706200 · 2003 · External reference
Role of Bile Acids and Their Receptors in Gastrointestinal and Hepatic Pathophysiology
10.1038/s41575-021-00566-7 · 2022 · External reference
Bile Acid‐Microbiota Crosstalk in Gastrointestinal Inflammation and Carcinogenesis
10.1038/nrgastro.2017.119 · 2018 · External reference
Targeting the Alternative Bile Acid Synthetic Pathway for Metabolic Diseases
10.1007/s13238-020-00804-9 · 2021 · External reference
Nuclear Receptor Control of Enterohepatic Circulation
10.1002/j.2040-4603.2012.tb00477.x · 2012 · External reference
Farnesoid X Receptor is Essential for Normal Glucose Homeostasis
10.1172/jci25604 · 2006 · External reference
A Regulatory Cascade of the Nuclear Receptors FXR, SHP‐1, and LRH‐1 Represses Bile Acid Biosynthesis
10.1016/s1097-2765(00)00051-4 · 2000 · External reference
Hepatic FXR‐FGF4 is Required for Bile Acid Homeostasis via an FGFR4‐LRH‐1 Signal Node Under Cholestatic Stress
10.1016/j.cmet.2024.09.008 · 2025 · External reference
Recent Insights Into Farnesoid X Receptor in Non‐Alcoholic Fatty Liver Disease
10.3748/wjg.v20.i37.13493 · 2014 · External reference
Hepatic Cytochrome P450 8B1 and Cholic Acid Potentiate Intestinal Epithelial Injury in Colitis by Suppressing Intestinal Stem Cell Renewal
10.1016/j.stem.2022.08.008 · 2022 · External reference
Aqueous Extract of Fermented Eucommia ulmoides Leaves Alleviates Hyperlipidemia by Maintaining Gut Homeostasis and Modulating Metabolism in High‐Fat Diet Fed Rats
10.1016/j.phymed.2023.155291 · 2024 · External reference
A New Perspective on NAFLD: Focusing on the Crosstalk Between Peroxisome Proliferator‐Activated Receptor Alpha (PPARα) and Farnesoid X Receptor (FXR)
10.1016/j.biopha.2022.113577 · 2022 · External reference
FXR Activation Protects Against NAFLD via Bile‐Acid‐Dependent Reductions in Lipid Absorption
10.1016/j.cmet.2021.06.012 · 2021 · External reference
Role of Bile Acids and GLP‐1 in Mediating the Metabolic Improvements of Bariatric Surgery
10.1053/j.gastro.2018.11.017 · 2019 · External reference
The Nuclear Bile Acid Receptor FXR is a PKA‐ and FOXA2‐Sensitive Activator of Fasting Hepatic Gluconeogenesis
10.1016/j.jhep.2018.06.022 · 2018 · External reference
Wedelolactone Alleviates Cholestatic Liver Injury by Regulating FXR‐Bile Acid‐NF‐κB/NRF2 Axis to Reduce Bile Acid Accumulation and Its Subsequent Inflammation and Oxidative Stress
10.1016/j.phymed.2023.155124 · 2024 · External reference
Melatonin Mitigates Aflatoxin B1‐Induced Liver Injury via Modulation of Gut Microbiota/Intestinal FXR/Liver TLR4 Signaling Axis in Mice
10.1111/jpi.12812 · 2022 · External reference
Bile Acids Induce Liver Fibrosis Through the NLRP3 Inflammasome Pathway and the Mechanism of FXR Inhibition of NLRP3 Activation
10.1007/s12072-023-10610-0 · 2024 · External reference
Dark and Bright Side of Targeting Fibroblast Growth Factor Receptor 4 in the Liver
10.1016/j.jhep.2021.07.029 · 2021 · External reference
IL‐31 Levels Correlate With Pruritus in Patients With Cholestatic and Metabolic Liver Diseases and is Farnesoid X Receptor Responsive in NASH
10.1002/hep.32599 · 2023 · External reference
Large‐Duct Cholangiopathies: Aetiology, Diagnosis and Treatment
10.1136/flgastro-2018-101098 · 2019 · External reference
The Microbiota and the Gut‐Liver Axis in Primary Sclerosing Cholangitis
10.1038/s41575-022-00690-y · 2023 · External reference
Protective and Aggressive Bacterial Subsets and Metabolites Modify Hepatobiliary Inflammation and Fibrosis in a Murine Model of PSC
10.1136/gutjnl-2021-326500 · 2023 · External reference
Clostridium scindens Protects Against Vancomycin‐Induced Cholestasis and Liver Fibrosis by Activating Intestinal FXR‐FGF15/19 Signaling
2025 · External reference
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96‐Week Open‐Label Extension in Patients With PSC
10.1016/j.cgh.2022.07.024 · 2023 · External reference
EASL Clinical Practice Guidelines: The Diagnosis and Management of Patients With Primary Biliary Cholangitis
10.1016/j.jhep.2017.03.022 · 2017 · External reference
Mechanisms and Molecules: What Are the Treatment Targets for Primary Biliary Cholangitis?
10.1002/hep.32405 · 2022 · External reference
Farnesoid X Receptor Agonist Tropifexor Attenuates Cholestasis in a Randomised Trial in Patients With Primary Biliary Cholangitis
10.1016/j.jhepr.2022.100544 · 2022 · External reference
Liver Fibrosis in NAFLD/NASH: From Pathophysiology Towards Diagnostic and Therapeutic Strategies
10.1016/j.mam.2023.101231 · 2024 · External reference
FXR Agonists in NASH Treatment
10.1016/j.jhep.2023.07.034 · 2023 · External reference
Noncanonical Farnesoid X Receptor Signaling Inhibits Apoptosis and Impedes Liver Fibrosis
10.1016/j.ebiom.2018.10.028 · 2018 · External reference
Natural Small Molecule Hinokitone Mitigates NASH Fibrosis by Targeting Regulation of FXR‐Mediated Hepatocyte Apoptosis
10.1016/j.jare.2024.12.016 · 2025 · External reference
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
10.1053/j.gastro.2007.04.061 · 2007 · External reference
Spontaneous Hepatocarcinogenesis in Farnesoid X Receptor‐Null Mice
10.1093/carcin/bgl249 · 2007 · External reference
Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development
10.1002/hep4.1263 · 2018 · External reference
Farnesoid X Receptor Associates With β‐Catenin and Inhibits Its Activity in Hepatocellular Carcinoma
10.18632/oncotarget.2899 · 2015 · External reference
FGF15 Activates Hippo Signaling to Suppress Bile Acid Metabolism and Liver Tumorigenesis
10.1016/j.devcel.2018.12.021 · 2019 · External reference
STAT Proteins ‐ Key Regulators of Anti‐Viral Responses, Inflammation, and Tumorigenesis in the Liver
10.1016/j.jhep.2012.01.029 · 2012 · External reference
Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade
10.1002/hep.31518 · 2021 · External reference
Mechanisms of NAFLD Development and Therapeutic Strategies
10.1038/s41591-018-0104-9 · 2018 · External reference
Tissue‐Specific Actions of FXR in Metabolism and Cancer
10.1016/j.bbalip.2014.08.005 · 2015 · External reference
Oligochitosan‐Based Nanovesicles for Nonalcoholic Fatty Liver Disease Treatment via the FXR/miR‐34a/SIRT1 Regulatory Loop
10.1016/j.actbio.2023.04.002 · 2023 · External reference
Cadmium Chloride Induces Non‐Alcoholic Fatty Liver Disease in Rats by Stimulating miR‐34a/SIRT1/FXR/p53 Axis
10.1016/j.scitotenv.2021.147182 · 2021 · External reference
SIRT1 Activation Synergizes With FXR Agonism in Hepatoprotection via Governing Nucleocytoplasmic Shuttling and Degradation of FXR
10.1016/j.apsb.2022.08.019 · 2023 · External reference
Intestinal Microbiome and NAFLD: Molecular Insights and Therapeutic Perspectives
10.1007/s00535-019-01649-8 · 2020 · External reference
The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats
10.1016/j.ajpath.2014.10.009 · 2015 · External reference
Microbiota‐Driven Gut Vascular Barrier Disruption is a Prerequisite for Non‐Alcoholic Steatohepatitis Development
10.1016/j.jhep.2019.08.005 · 2019 · External reference
Gut‐Liver Axis: Pathophysiological Concepts and Clinical Implications
10.1016/j.cmet.2022.09.017 · 2022 · External reference
Ileitis Promotes MASLD Progression via Bile Acid Modulation and Enhanced TGR5 Signaling in Ileal CD8+ T Cells
10.1016/j.jhep.2023.12.024 · 2024 · External reference
Intestinal Flora Is a Key Factor in Insulin Resistance and Contributes to the Development of Polycystic Ovary Syndrome
10.1210/endocr/bqab118 · 2021 · External reference
FXR Regulates Intestinal Cancer Stem Cell Proliferation
10.1016/j.cell.2019.01.036 · 2019 · External reference
Lithocholic Acid Activates Mas‐Related G Protein‐Coupled Receptors, Contributing to Itch in Mice
10.4062/biomolther.2021.059 · 2022 · External reference
Non‐Invasive Evaluation of Response to Obeticholic Acid in Patients With NASH: Results From the REGENERATE Study
10.1016/j.jhep.2021.10.029 · 2022 · External reference
Obeticholic Acid and Other Farnesoid‐X‐Receptor (FXR) Agonists in the Treatment of Liver Disorders
10.3390/ph18091424 · 2025 · External reference
Discovery of (E)‐3‐(3‐((2‐Cyano‐4′‐Dimethylaminobiphenyl‐4‐Ylmethyl)cyclohexanecarbonylamino)‐5‐Fluorophenyl)acrylic Acid Methyl Ester, an Intestine‐Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis
10.1021/acs.jmedchem.2c00641 · 2022 · External reference
Obeticholic Acid and INT‐767 Modulate Collagen Deposition in a NASH In Vitro Model
10.1038/s41598-020-58562-x · 2020 · External reference
Farnesoid X Receptor Agonist for the Treatment of Chronic Hepatitis B: A Safety Study
10.1111/jvh.13608 · 2021 · External reference
Emodin Palliates High‐Fat Diet‐Induced Nonalcoholic Fatty Liver Disease in Mice via Activating the Farnesoid X Receptor Pathway
10.1016/j.jep.2021.114340 · 2021 · External reference
Discovery of 4‐Aminophenylacetamide Derivatives as Intestine‐Specific Farnesoid X Receptor Antagonists for the Potential Treatment of Nonalcoholic Steatohepatitis
10.1016/j.ejmech.2023.115992 · 2024 · External reference
Discovery of Orally Active and Nonsteroidal Farnesoid X Receptor (FXR) Antagonist With Propensity for Accumulation and Responsiveness in Ileum
10.1021/acsmedchemlett.0c00640 · 2021 · External reference
Obeticholic Acid‐A New Therapy in PBC and NASH
10.1093/bmb/ldaa006 · 2020 · External reference
Safety, Pharmacokinetics and Pharmacodynamics of Obeticholic Acid in Subjects With Fibrosis or Cirrhosis From NASH
10.1111/liv.15816 · 2024 · External reference
FXR Agonist GW4064 Alleviates Endotoxin‐Induced Hepatic Inflammation by Repressing Macrophage Activation
10.3748/wjg.v20.i39.14430 · 2014 · External reference
Exposure to the Synthetic FXR Agonist GW4064 Causes Alterations in Gene Expression and Sublethal Hepatotoxicity in Eleutheroembryo Medaka ( Oryzias latipes )
10.1016/j.taap.2009.11.022 · 2010 · External reference
Structural Insights Into Molecular and Cellular Level FXR Binding Potentials of GW4064 and LY2562175 Hybrids by Multi In Silico Modelling Analyses
10.1007/s00894-025-06336-5 · 2025 · External reference
Dual Agonist of Farnesoid X Receptor and Takeda G Protein‐Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo
10.1002/hep.31712 · 2021 · External reference
Functional Characterization of the Semisynthetic Bile Acid Derivative INT‐767, a Dual Farnesoid X Receptor and TGR5 Agonist
10.1124/mol.110.064501 · 2010 · External reference
FXR‐Targeted Drug Discovery: Recent Advances and Therapeutic Perspectives
10.1016/j.ejmech.2025.118332 · 2026 · External reference
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Cilofexor, a Novel Nonsteroidal Farnesoid X Receptor Agonist, in Healthy Volunteers
10.1111/cts.13469 · 2023 · External reference
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
10.3390/ijms241612748 · 2023 · External reference
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non‐Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
10.1002/cpdd.762 · 2020 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
FXR Antagonist FLG249 Lowers Hepatic Triacylglycerol and Serum Cholesterol Level in High‐Fat Diet‐Induced Obese Mice
10.1248/bpb.b24-00311 · 2024 · External reference
Pectin Mediates the Mechanism of Host Blood Glucose Regulation Through Intestinal Flora
10.1080/10408398.2023.2173719 · 2024 · External reference
Effect of Chenodeoxycholic Acid and the Bile Acid Sequestrant Colesevelam on Glucagon‐Like Peptide‐1 Secretion
10.1111/dom.12648 · 2016 · External reference
Gut Liver Brain Axis in Diseases: The Implications for Therapeutic Interventions
10.1038/s41392-023-01673-4 · 2023 · External reference
Red Ginseng Extracts Ameliorate High‐Fat Diet‐Induced Obesity and Insulin Resistance by Activating the Intestinal TGR5‐Mediated Bile Acids Signaling Pathway
10.1016/j.phymed.2023.154982 · 2023 · External reference
Crosstalk Between Glucagon‐Like Peptide 1 and Gut Microbiota in Metabolic Diseases
10.1128/mbio.02032-23 · 2024 · External reference
Saponins From Camellia sinensis Seeds Stimulate GIP Secretion in Mice and STC‐1 Cells via SGLT1 and TGR5
10.3390/nu14163413 · 2022 · External reference
TGR5 Receptors in SF1‐Expressing Neurons of the Ventromedial Hypothalamus Regulate Glucose Homeostasis
10.1016/j.molmet.2024.102071 · 2025 · External reference
Inhibition of Fatty Acid Uptake by TGR5 Prevents Diabetic Cardiomyopathy
10.1038/s42255-024-01036-5 · 2024 · External reference
Brown Adipose Tissue, Diet‐Induced Thermogenesis, and Thermogenic Food Ingredients: From Mice to Men
10.3389/fendo.2020.00222 · 2020 · External reference
Non‐Shivering Thermogenesis Signalling Regulation and Potential Therapeutic Applications of Brown Adipose Tissue
10.7150/ijbs.60354 · 2021 · External reference
Mechanism of Action of the Bile Acid Receptor TGR5 in Obesity
10.1016/j.apsb.2023.11.011 · 2024 · External reference
Deiodinases and the Metabolic Code for Thyroid Hormone Action
10.1210/endocr/bqab059 · 2021 · External reference
Mitochondrial Patch Clamp of Beige Adipocytes Reveals UCP1‐Positive and UCP1‐Negative Cells Both Exhibiting Futile Creatine Cycling
10.1016/j.cmet.2017.03.002 · 2017 · External reference
Intestinal Hypoxia‐Inducible Factor 2α Regulates Lactate Levels to Shape the Gut Microbiome and Alter Thermogenesis
10.1016/j.cmet.2021.07.007 · 2021 · External reference
Gut Microbiota‐Mediated Secondary Bile Acid Alleviates Staphylococcus aureus ‐Induced Mastitis Through the TGR5‐cAMP‐PKA‐NF‐κB/NLRP3 Pathways in Mice
10.1038/s41522-023-00374-8 · 2023 · External reference
Natural Bear Bile Powder Suppresses Neuroinflammation in Lipopolysaccharide‐Treated Mice via Regulating TGR5/AKT/NF‐κB Signaling Pathway
10.1016/j.jep.2022.115063 · 2022 · External reference
TGR5 Regulates Macrophage Inflammation in Nonalcoholic Steatohepatitis by Modulating NLRP3 Inflammasome Activation
10.3389/fimmu.2020.609060 · 2020 · External reference
Traditional Chinese Medicine Pien‐Tze‐Huang Ameliorates LPS‐Induced Sepsis Through Bile Acid‐Mediated Activation of TGR5‐STAT3‐A20 Signalling
10.1016/j.jpha.2023.12.005 · 2024 · External reference
Bile Acid‐Activated Receptors and the Regulation of Macrophages Function in Metabolic Disorders
10.1016/j.coph.2020.04.008 · 2020 · External reference
The Cholangiocyte Glycocalyx Stabilizes the ‘Biliary HCO3 Umbrella’: An Integrated Line of Defense Against Toxic Bile Acids
10.1159/000371864 · 2015 · External reference
The Membrane‐Bound Bile Acid Receptor TGR5 Is Localized in the Epithelium of Human Gallbladders
10.1002/hep.23032 · 2009 · External reference
Bile Acid Binding Resin Improves Metabolic Control Through the Induction of Energy Expenditure
10.1371/journal.pone.0038286 · 2012 · External reference
Targeted Disruption of G Protein‐Coupled Bile Acid Receptor 1 (Gpbar1/M‐Bar) in Mice
10.1677/joe.1.06546 · 2006 · External reference
TGR5 Contributes to Glucoregulatory Improvements After Vertical Sleeve Gastrectomy in Mice
10.1136/gutjnl-2015-309871 · 2017 · External reference
Role of Bile Acids in the Regulation of Food Intake, and Their Dysregulation in Metabolic Disease
10.3390/nu13041104 · 2021 · External reference
Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD
10.1016/j.cgh.2023.12.009 · 2024 · External reference
Intestinal TGR5 Agonism Improves Hepatic Steatosis and Insulin Sensitivity in Western Diet‐Fed Mice
10.1152/ajpgi.00300.2018 · 2019 · External reference
Modulation of Endothelium‐Derived Nitric Oxide Production and Activity by Taurine and Taurine‐Conjugated Bile Acids
10.1016/j.niox.2019.10.008 · 2020 · External reference
Bile Acids Control Inflammation and Metabolic Disorder Through Inhibition of NLRP3 Inflammasome
10.1016/j.immuni.2016.10.009 · 2016 · External reference
The Crosstalk Between Gut Microbiota and Bile Acids Promotes the Development of Non‐Alcoholic Fatty Liver Disease
10.3390/microorganisms11082059 · 2023 · External reference
Downregulation of TGR5 (GPBAR1) in Biliary Epithelial Cells Contributes to the Pathogenesis of Sclerosing Cholangitis
10.1016/j.jhep.2021.03.029 · 2021 · External reference
TGR5 Protects Against Cholestatic Liver Disease via Suppressing the NF‐κB Pathway and Activating the Nrf2/HO‐1 Pathway
10.21037/atm-21-2631 · 2021 · External reference
Bile Acid Receptors in the Biliary Tree: TGR5 in Physiology and Disease
10.1016/j.bbadis.2017.08.021 · 2018 · External reference
Synergistic Anti‐Inflammatory Effect of Gut Microbiota and Lithocholic Acid on Liver Fibrosis
10.1007/s00011-022-01629-4 · 2022 · External reference
Agonism for the Bile Acid Receptor GPBAR1 Reverses Liver and Vascular Damage in a Mouse Model of Steatohepatitis
10.1096/fj.201801373rr · 2019 · External reference
Research Progress of Takeda G Protein‐Coupled Receptor 5 in Metabolic Syndrome
10.3390/molecules28155870 · 2023 · External reference
Targeting TGR5 to Mitigate Liver Fibrosis: Inhibition of Hepatic Stellate Cell Activation Through Modulation of Mitochondrial Fission
10.1016/j.intimp.2024.112831 · 2024 · External reference
Deficiency of G‐Protein‐Coupled Bile Acid Receptor Gpbar1 (TGR5) Enhances Chemically Induced Liver Carcinogenesis
10.1002/hep.26019 · 2013 · External reference
Smoking as an Independent Risk Factor for Hepatocellular Carcinoma due to the α7‐Nachr Modulating the JAK2/STAT3 Signaling Axis
10.3390/jcm8091391 · 2019 · External reference
Pleiotropic Roles of Bile Acids in Metabolism
10.1016/j.cmet.2013.03.013 · 2013 · External reference
Structure‐Activity Relationship Study of Betulinic Acid, a Novel and Selective TGR5 Agonist, and Its Synthetic Derivatives: Potential Impact in Diabetes
10.1021/jm900872z · 2010 · External reference
Discovery of 6alpha‐Ethyl‐23(S)‐Methylcholic Acid (S‐EMCA, INT‐777) as a Potent and Selective Agonist for the TGR5 Receptor, a Novel Target for Diabesity
10.1021/jm901390p · 2009 · External reference
Combinatorial Targeting of G‐Protein‐Coupled Bile Acid Receptor 1 and Cysteinyl Leukotriene Receptor 1 Reveals a Mechanistic Role for Bile Acids and Leukotrienes in Drug‐Induced Liver Injury
10.1002/hep.32787 · 2023 · External reference
Investigation of the Potential Role of TGR5 in Pancreatic Cancer by a Comprehensive Molecular Experiments and the Liquid Chromatography Mass Spectrometry (LC‐MS) Based Metabolomics
10.1007/s12672-022-00504-2 · 2022 · External reference
Sodium Butyrate Regulates Macrophage Polarization by TGR5/β‐Arrestin2 In Vitro
2025 · External reference
Targeting of a Bile Acid Receptor, Takeda G Protein Receptor 5 [TGR5], by a Novel First‐in‐Class Competitive Antagonist, SBI‐364, Diminishes Hepatic and Renal Cystogenesis in Polycystic Liver and Kidney Disease
10.1021/acsptsci.4c00701 · 2025 · External reference
Bile Acid Network and Vascular Calcification‐Associated Diseases: Unraveling the Intricate Connections and Therapeutic Potential
10.2147/cia.s431220 · 2023 · External reference
Activation of TGR5 in the Injured Nerve Site According to a Prevention Protocol Mitigates Partial Sciatic Nerve Ligation‐Induced Neuropathic Pain by Alleviating Neuroinflammation
10.1097/j.pain.0000000000003460 · 2025 · External reference
The Gut Microbiome‐Bile Acid‐FXR Interplay: A Pivotal Axis in Metabolic and Gastrointestinal Diseases
10.1080/19490976.2026.2665890 · 2026 · External reference
Bile Acid Signaling and Liver Regeneration
10.1016/j.bbagrm.2014.05.021 · 2015 · External reference
Molecular Regulation of Bile Acid Homeostasis
10.1124/dmd.121.000643 · 2022 · External reference
Gut Microbiome‐Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non‐Alcoholic Fatty Liver Disease
10.3389/fmicb.2021.761836 · 2021 · External reference
Bile Acid and Nonalcoholic Steatohepatitis: Molecular Insights and Therapeutic Targets
10.1016/j.jare.2023.06.009 · 2024 · External reference
Microbially Conjugated Bile Salts Found in Human Bile Activate the Bile Salt Receptors TGR5 and FXR
2024 · External reference
The Role of Bile Salts in Liver Regeneration
10.1007/s12072-016-9723-8 · 2016 · External reference
Crosstalk Between Bile Acids and Intestinal Epithelium: Multidimensional Roles of Farnesoid X Receptor and Takeda G Protein Receptor 5
10.3390/ijms26094240 · 2025 · External reference
Genome‐Wide Tissue‐Specific Farnesoid X Receptor Binding in Mouse Liver and Intestine
10.1002/hep.23450 · 2010 · External reference
The Pathophysiological Function of Non‐Gastrointestinal Farnesoid X Receptor
10.1016/j.pharmthera.2021.107867 · 2021 · External reference
Role of the G Protein‐Coupled Bile Acid Receptor TGR5 in Liver Damage
10.1159/000450917 · 2017 · External reference
TGR5 is Essential for Bile Acid‐Dependent Cholangiocyte Proliferation In Vivo and In Vitro
10.1136/gutjnl-2015-309458 · 2016 · External reference
